FDA Approves Rituximab Biosimilar for Multiple Blood Cancer Indications - www.oncnursingnews.com/

FDA Approves Rituximab Biosimilar for Multiple Blood Cancer Indications  www.oncnursingnews.com/

The Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) for the treatment of blood cancers.